In March 2025, the company announced new plans for any direct-to-purchaser supplying of its Wegovy weight loss drug. The company recognized a completely new pharmacy, known as NovoCare, which might demand buyers $499 a month for access to the drug, lower than fifty percent the cost of the drug by way of other pharmaceutical distribution networks.[5